Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...
Hosted on MSN

Moderna stock jumps after FDA reverses course on flu shot

Shares of Moderna MRNA rose 6% on Wednesday after the company announced that the FDA agreed to review its regulatory filing seeking approval for its seasonal influenza vaccine, mRNA-1010. A final ...

First European human case of H9N2 bird flu reported in Italy: What you need to know

The first human case of H9N2 influenza virus (bird flu) has been reported in Europe. A human infection was recorded by the ...
Honolulu Star-Advertiser

FDA reverses course, will review Moderna’s flu vaccine application

Moderna said today the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling drugmaker ...

Will an mRNA Flu Vaccine Offer Better Protection?

The FDA is reviewing the first mRNA flu vaccine for adults 50 and older. Learn how this technology could lead to faster and ...
Yahoo

FDA plans review of Moderna flu vaccine for older adults

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration will review Moderna's mRNA 1010 flu vaccine for older adults, which could make it available ...
The Lancet

EMA approves combined COVID-19 and flu mRNA vaccine

The EMA approved Moderna's mRNA COVID-19 and flu vaccine, but US political battles and funding cuts threaten the future of mRNA vaccine innovation. Talha Burki reports.